LLY Eli Lilly and Company

Elanco Names Todd S. Young as New Chief Financial Officer

Regulatory News:

Elanco Animal Health Incorporated (NYSE:ELAN), today named Todd S. Young as executive vice president and chief financial officer (CFO), joining Elanco’s Executive Committee and reporting to Elanco president and chief executive officer, Jeffrey N. Simmons.

Young starts his new position at Elanco on November 1 at the company’s Greenfield, Indiana headquarters. Lucas Montarce, who has been serving as acting Elanco CFO, will return to Eli Lilly and Company as vice president and CFO of Lilly’s International Business Unit.

“I am pleased to welcome Todd to the Elanco Executive Team,” said Jeff Simmons, president and CEO of Elanco. “His deep financial expertise combined with his pharmaceutical industry knowledge make him an excellent addition to Elanco at this exciting time in our company’s history. We also thank Lucas Montarce for his dedication and commitment stepping in during a critical time.”

Young will have responsibility for Elanco’s financial operations. He has more than 20 years’ experience in a wide range of financial roles. Most recently, he was executive vice president and CFO for ACADIA Pharmaceuticals Inc. in San Diego. He also spent several years in varying financial leader roles at Baxter International and worked on the spin-off of Baxalta, which he then joined as senior vice president and treasurer. He started his career at law firm Sidley Austin L.L.P.

Over the past 20 years, Young has had experience in all sectors of corporate financial operations, including tax, treasury, mergers and acquisitions, and leading and building finance teams. He also spent time in international markets throughout his career.

About Elanco Animal Health

Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life – all to advance the health of animals, people and the planet. Learn more at .

EN
30/10/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eli Lilly and Company

Moody's Ratings says that Lilly's acquisition of Centessa expands neur...

Announcement: Moody's Ratings says that Lilly's acquisition of Centessa expands neuroscience portfolio with mid-stage narcolepsy pipeline. Global Credit Research- 01 Apr 2026. New York, April 01, 2026-- Moody's Ratings said that Eli Lilly and Company's Centessa acquisition adds another long-term growth platform to Lilly's neuroscience franchise with the potential to further diversify the company beyond its market-leading incretin portfolio.

Eli Lilly and Company - December 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Curtis Yeung ... (+2)
  • Curtis Yeung
  • Greater China Research Team

Greater China Daily: Monday, February 16, 2026

Top Stories Economics | Money Supply M0 growth was weaker in Jan 26 due to Chinese New Year effects, while M2 growth rose to 9.0% yoy, the highest since 2023. New bank loans surged to Rmb4.71t and new TSF rose to Rmb7.22t, both above consensus forecasts. However, outstanding bank loan growth fell to a record-low 6.1% yoy, highlighting fragile underlying credit demand despite strong front-loaded lending. Sector Update | Healthcare The HSHCI rose 1.8%, outperforming the HSI, which declined by 3.8...

Eli Lilly and Company: Update to credit analysis following outlook cha...

Our credit view of this issuer reflects its growth portfolio in oncology, neuroscience and immunology, offset by its revenue concentration in diabetes / metabolic conditions.

Moody's Ratings affirms Eli Lilly's Aa3 rating; revises outlook to pos...

Moody's Ratings (Moody's) affirmed the ratings of Eli Lilly and Company ("Lilly") including the Aa3 senior unsecured notes ratings and long-term issuer rating, the (P)Aa3 senior unsecured shelf and medium term note program ratings, and the Prime-1 short-term commercial paper rating. At the same time...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch